Beam Therapeutics(us:BEAM)

19.53

-12.07%

Updated on 2025-03-31

Open:21.25
Close:19.53
High:21.38
Low:18.30
Prev Close:22.21
Volume:5.74M
Turnover:110.74M
Turnover Ratio:5.75%
Shares:99.84M
MarketCap:1.95B
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-30758510.01%312
2024-03-312306965555284.66%527963
2023-12-312216864528384.09%336495
2023-09-302146674657984.08%337865
2023-06-302186350428181.46%207676
2023-03-312275956547980.02%267687
2022-12-312455580163678.29%268694
2022-09-302435404280176.70%427092
dateorgNametotalratiochangeShareschangeRatio
2024-06-30Farallon Capital Management Llc79131239.60%340137075.39%
2024-06-30Vanguard Group Inc79003799.59%3216114.24%
2024-06-30Blackrock Inc.76343799.27%92875313.85%
2024-06-30Ark Investment Management Llc76261399.26%-556035-6.80%
2024-06-30Arch Venture Management, Llc54430396.61%5443039
2024-06-30Fmr Llc44076955.35%-486758-9.95%
2024-06-30State Street Corp34921554.24%-239037-6.41%
2024-06-30Mwg Management Ltd.22669342.75%-80000-3.41%
2024-06-30Nikko Asset Management Americas, Inc.22244152.70%-137402-5.82%
2024-06-30Sumitomo Mitsui Trust Holdings, Inc.22244152.70%-137402-5.82%

About

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Address:238 Main Street,9th floor

Market Movers